Akouos
About Akouos
Akouos is a biotechnology company focused on restoring and preserving hearing. Akouos’s scientific founders are world leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy
YEAR FOUNDED:
2017
LEADERSHIP:
Founder & CEO: Dr. Manny Simons
21 articles with Akouos
-
Akouos to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
11/23/2020
Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., CEO, President and co-founder, participated in a pre-recorded fireside chat that will be published today as part of the Piper Sandler 32 nd Annual Virtual Healthcare Conference taking place December 1 to 3, 2020. Th
-
Akouos Reports Third Quarter 2020 Financial Results and Provides Business Highlights
11/12/2020
Expanded leadership team with appointment of Sachiyo Minegishi as CFO and promotion of Jennifer Wellman to COO
-
BioSpace Movers & Shakers, Oct. 2
10/2/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Akouos Announces Key Leadership Appointments
10/1/2020
Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced the appointment of Sachiyo Minegishi as chief financial officer
-
Akouos to Present at Cantor Global Virtual Healthcare Conference - Sep 08, 2020
9/8/2020
Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced that Manny Simons, Ph.D., M.B.A., CEO, President and co-founder, will participate in a fireside chat at the Cantor Global Virtual Healthcare Conference on Tuesday, September 15 at 8:00 a.m. ET.
-
Akouos Reports Second Quarter 2020 Financial Results and Provides Business Highlights
8/13/2020
Company plans to advance lead product candidate, AK-OTOF, for the treatment of hearing loss due to mutations in the OTOF gene, to IND submission in 2021 and advance development programs spanning multiple inner ear disorders
-
BioSpace Movers & Shakers, Aug. 7
8/7/2020
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers and Shakers. -
Akouos Announces Expansion of Executive Team and Board of Directors
8/5/2020
Alan Smith, Ph.D., Joins as Chief Technology Officer Saira Ramasastry Joins Board of Directors; Arthur Tzianabos, Ph.D., Role Expanded to Chairman
-
Akouos to Present at BTIG Virtual Biotechnology Conference
8/3/2020
Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for people worldwide who live with disabling hearing loss, today announced that Manny Simons, Ph.D., M.B.A., CEO, President and co-founder, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 10 at 10:30 a.m. ET. A live webcast of the fireside chat will be accessible through the i
-
Akouos Announces Closing of Initial Public Offering - June 30, 2020
6/30/2020
Akouos, Inc. announced the closing of its initial public offering of 14,375,000 shares of common stock at a public offering price of $17.00 per share, including 1,875,000 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for gross proceeds of $244.4 million...
-
Akouos Announces Pricing of Initial Public Offering
6/25/2020
Akouos, Inc. (“Akouos”) (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss, today announced the pricing of its initial public offering of 12,500,000 shares of common stock at a public offering price of $17.00 per share, for gross proceeds of $212.5 million, before underwr
-
Three months after hearing loss-focused company Akouos secured $105 million in a Series B financing round, the Boston-based company is eying an initial public offering valued at about $100 million.
-
Akouos to Present Data from Inner Ear Gene Therapy Platform at 23rd ASGCT Annual Meeting
5/11/2020
Akouos, a precision genetic medicine company developing gene therapies to potentially restore, improve and preserve hearing, announced that data from its inner ear gene therapy platform will be presented during the 23rd American Society of Gene and Cell Therapy Annual Meeting, which will be held virtually May 12-15, 2020.
-
Akouos Closes $105 Million Series B Financing
3/3/2020
Appoints Vicki Sato, Ph.D., and Heather Preston, M.D., to Board of Directors
-
BioSpace Movers & Shakers, Jan. 17
1/17/2020
Pharma companies add new members to executive ranks and boards of directors. -
Akouos Appoints Rabia Gurses Ozden, M.D., as Chief Development Officer
10/24/2019
Akouos, a precision genetic medicine company developing gene therapies to restore and preserve hearing, announced the appointment of Rabia Gurses Ozden, M.D., as chief development officer.
-
Case Western Reserve University and Akouos sign exclusive licensing agreement to advance development of gene therapy technology as a potential treatment for a type of Usher syndrome
9/8/2019
Case Western Reserve University and Boston-based Akouos have entered into an exclusive licensing agreement to develop a patented gene therapy with the potential to treat hearing loss associated with a type of Usher syndrome, the most common deaf-blind disorder.
-
Akouos Announces Executive Leadership Team Appointments
9/3/2019
Gregory Robinson, Ph.D., Appointed to Chief Scientific Officer Co-Founder Michael McKenna, M.D., Expands Role to Full-Time Chief Medical Officer
-
Akouos to Participate in Upcoming Investor Conferences - Aug. 9, 2019
8/9/2019
Akouos announced management will be attending the following investor conferences in August
-
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.